RS64815B1 - Lečenje ćelija kancera koje prekomerno eksprimiraju receptore za somatostatin primenom derivata oktreotida heliranih sa radioizotopima - Google Patents
Lečenje ćelija kancera koje prekomerno eksprimiraju receptore za somatostatin primenom derivata oktreotida heliranih sa radioizotopimaInfo
- Publication number
- RS64815B1 RS64815B1 RS20231056A RSP20231056A RS64815B1 RS 64815 B1 RS64815 B1 RS 64815B1 RS 20231056 A RS20231056 A RS 20231056A RS P20231056 A RSP20231056 A RS P20231056A RS 64815 B1 RS64815 B1 RS 64815B1
- Authority
- RS
- Serbia
- Prior art keywords
- ocreotide
- chelated
- radioisotopes
- derivatives
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 108050001286 Somatostatin Receptor Proteins 0.000 title 1
- 102000011096 Somatostatin receptor Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762445541P | 2017-01-12 | 2017-01-12 | |
| EP18703122.4A EP3568205B1 (en) | 2017-01-12 | 2018-01-12 | Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes |
| PCT/US2018/013640 WO2018132751A1 (en) | 2017-01-12 | 2018-01-12 | Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS64815B1 true RS64815B1 (sr) | 2023-12-29 |
Family
ID=61157311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20231056A RS64815B1 (sr) | 2017-01-12 | 2018-01-12 | Lečenje ćelija kancera koje prekomerno eksprimiraju receptore za somatostatin primenom derivata oktreotida heliranih sa radioizotopima |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11541133B2 (sr) |
| EP (1) | EP3568205B1 (sr) |
| JP (1) | JP7084417B2 (sr) |
| KR (1) | KR102296752B1 (sr) |
| CN (1) | CN110678227B (sr) |
| AU (1) | AU2018207190B2 (sr) |
| CA (1) | CA3050094C (sr) |
| DK (1) | DK3568205T3 (sr) |
| ES (1) | ES2960030T3 (sr) |
| FI (1) | FI3568205T3 (sr) |
| HR (1) | HRP20231458T1 (sr) |
| HU (1) | HUE063981T2 (sr) |
| IL (1) | IL268012B (sr) |
| LT (1) | LT3568205T (sr) |
| PL (1) | PL3568205T3 (sr) |
| PT (1) | PT3568205T (sr) |
| RS (1) | RS64815B1 (sr) |
| SI (1) | SI3568205T1 (sr) |
| WO (1) | WO2018132751A1 (sr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3784294A4 (en) * | 2018-04-27 | 2022-01-05 | University of Iowa Research Foundation | COMPOSITIONS FOR CHELATING METALS AT LOW TEMPERATURES |
| KR20220132556A (ko) * | 2020-01-29 | 2022-09-30 | 유니버시티 오브 아이오와 리써치 파운데이션 | 암에 대한 펩티드 수용체 표적화 방사성핵종 치료의 테라노스틱 성능을 개선하기 위한 구조 최적화 방법 |
| US20230382819A1 (en) * | 2020-10-14 | 2023-11-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Processes for synthesis of alpha-emitting radiopharmaceuticals |
| NL2028075B1 (en) * | 2021-04-26 | 2022-11-03 | Alphathera Ag | Targeting system for cancer comprising a radioisotope |
| CN113277989B (zh) * | 2021-04-27 | 2022-05-31 | 中南大学湘雅医院 | 一种68Ga标记的分子探针、制备方法及其应用 |
| US11541134B1 (en) | 2021-08-02 | 2023-01-03 | Rayzebio, Inc. | Stabilized compositions of radionuclides and uses thereof |
| EP4282439A1 (en) | 2022-05-23 | 2023-11-29 | Erasmus University Rotterdam Medical Center | Radioisotope labeled sstr2-agonists with linkers |
| WO2024101993A1 (en) | 2022-11-09 | 2024-05-16 | Coretag IP B.V. | Targeting system for cancer treatment |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004017D0 (en) | 1990-02-22 | 1990-04-18 | Krenning Eric P | Improvements in or relating to organic compounds |
| US6017512A (en) * | 1992-06-23 | 2000-01-25 | Diatide, Inc. | Radiolabeled peptides |
| GB9417873D0 (en) | 1994-09-06 | 1994-10-26 | Sandoz Ltd | Organic compounds |
| US5830431A (en) | 1995-06-07 | 1998-11-03 | Mallinckrodt Medical, Inc. | Radiolabeled peptide compositions for site-specific targeting |
| MY147327A (en) | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
| US7361346B1 (en) | 1996-05-15 | 2008-04-22 | Altarex Corp. | Therapeutic compositions that produce an immune response |
| US6207805B1 (en) | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
| US6866837B2 (en) | 1998-06-05 | 2005-03-15 | Mallinckrodt Inc. | Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors |
| US6926883B1 (en) | 1999-06-29 | 2005-08-09 | Mallinckrodt Inc | Group (VII) transition-metal complexes with multidentate aminopolycarboxylate ligands and a kit for producing them |
| US6358491B1 (en) | 1999-08-27 | 2002-03-19 | Berlex Laboratories, Inc. | Somatostatin analogs |
| NZ522200A (en) | 2000-04-26 | 2004-07-30 | Biosynthema Inc | RGD (ARG-GLY-ASP) coupled to (neuro)peptides |
| AU1123202A (en) | 2000-09-15 | 2002-03-26 | Sloan Kettering Inst Cancer | Targeted alpha particle therapy using actinium-225 conjugates |
| DE60231801D1 (de) | 2001-04-23 | 2009-05-14 | Mallinckrodt Inc | Tc und re markierte radioaktive glycosylierte octreotid-derivate |
| EP1283216A1 (en) | 2001-08-10 | 2003-02-12 | Mallinckrodt Inc. | Somatostatin analogues binding to all somatostatin receptor subtypes and their use |
| US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
| US7122622B2 (en) * | 2002-04-16 | 2006-10-17 | Biosynthema Inc. | Peptide compounds having improved binding affinity to somatostatin receptors |
| EP1793868B1 (en) * | 2004-09-23 | 2010-12-29 | Guerbet | Liposomal contrast agents for cest imaging |
| US20070025910A1 (en) * | 2005-07-29 | 2007-02-01 | Norenberg Jeffrey P | Anticancer therapy |
| US8097237B2 (en) | 2005-08-23 | 2012-01-17 | Stc.Unm | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma |
| EP1988925A2 (en) | 2006-02-24 | 2008-11-12 | Mallinckrodt, Inc. | Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates |
| ES2397116T3 (es) | 2006-03-14 | 2013-03-04 | Mallinckrodt, Inc. | Complejos de metal de derivados de tretraazamacrociclo |
| US20160045626A1 (en) * | 2007-01-11 | 2016-02-18 | Immunomedics, Inc. | Methods and Compositions for Improved Labeling of Targeting Peptides |
| BRPI0809442A2 (pt) | 2007-03-27 | 2014-09-09 | Radiomedix Inc | Composições para terapia e formação de imagens direcionada |
| US20100316566A1 (en) | 2008-02-27 | 2010-12-16 | Radiomedix Inc. | Radiolabeled hedgehog derivatives for imaging and therapy |
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| US8623322B2 (en) | 2008-06-13 | 2014-01-07 | Stc.Unm | Non-invasive diagnostic agents and methods of diagnosing infectious disease |
| ES2743412T3 (es) | 2008-09-30 | 2020-02-19 | Curium Us Llc | Productos conjugados de hexosa y compuestos de coordinación de metales para la generación de imágenes |
| US9603954B2 (en) | 2009-07-22 | 2017-03-28 | Actinium Pharmaceuticals Inc. | Methods for generating radioimmunoconjugates |
| US8986651B2 (en) | 2009-11-30 | 2015-03-24 | Stc.Unm | Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same |
| WO2012027556A1 (en) | 2010-08-25 | 2012-03-01 | William Marsh Rice University | Nanostructures comprising radioisotopes and/or metals |
| US9180214B1 (en) | 2011-04-22 | 2015-11-10 | Stc.Unm | Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer |
| US9550001B2 (en) | 2011-06-20 | 2017-01-24 | Radiomedix Inc. | Compositions, methods of synthesis and use of carbohydrate targeted agents |
| ES2842998T3 (es) * | 2011-08-31 | 2021-07-15 | Somscan Aps | Trazador TEP para imágenes de tumores neuroendocrinos |
| JP2015501654A (ja) * | 2011-12-13 | 2015-01-19 | ノルディック ナノベクター アーエス | 治療用キメラ型抗ｃｄ３７抗体ｈｈ１ |
| EP3536347A1 (en) | 2012-09-25 | 2019-09-11 | Advanced Accelerator Applications USA, Inc. | Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer |
| EP2920156B9 (en) | 2012-10-02 | 2017-04-19 | Guerbet | Process for the preparation of macrocyclic polyazacarboxylate ligands and chelates |
| US20140147381A1 (en) * | 2012-11-29 | 2014-05-29 | Gregory David Espenan | 89zr compounds, to include somatostatin, apparatus and products comprising such compounds, methods of making same, and methods of using same for radio imaging and/or treatment |
| EP3011339A4 (en) | 2013-06-18 | 2017-01-25 | Aminomedix Inc. | Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids |
| US20150157742A1 (en) | 2013-12-11 | 2015-06-11 | The European Atomic Energy Community (Euratom), Represented By The European Commission | SYNTHESIS OF BIOLOGICAL COMPOUNDS LABELED WITH THE ALPHA EMITTER Ac-225 |
| GB201417067D0 (en) * | 2014-09-26 | 2014-11-12 | South African Nuclear Energy | Radiopharmaceutical conjugate |
| WO2016138448A1 (en) * | 2015-02-27 | 2016-09-01 | Schmitthenner Hans F | Transmetalation methods for the synthesis of pet and spect imaging agents |
| EP3294316A4 (en) * | 2015-05-06 | 2018-10-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Radiotherapeutic and companion imaging agents to target mc1r |
| EP3111959B1 (en) * | 2015-07-03 | 2017-09-13 | Oncoinvent AS | Radiotherapeutic particles and suspensions |
| CN106084005B (zh) * | 2016-06-15 | 2020-02-14 | 广州军区广州总医院 | 靶向生长抑素受体的Al18F-NOTA-PEG6-TATE及其制备方法和应用 |
| FR3069245B1 (fr) * | 2017-07-21 | 2019-07-26 | Guerbet | Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales |
| KR20220132556A (ko) * | 2020-01-29 | 2022-09-30 | 유니버시티 오브 아이오와 리써치 파운데이션 | 암에 대한 펩티드 수용체 표적화 방사성핵종 치료의 테라노스틱 성능을 개선하기 위한 구조 최적화 방법 |
-
2018
- 2018-01-12 LT LTEPPCT/US2018/013640T patent/LT3568205T/lt unknown
- 2018-01-12 PT PT187031224T patent/PT3568205T/pt unknown
- 2018-01-12 HR HRP20231458TT patent/HRP20231458T1/hr unknown
- 2018-01-12 HU HUE18703122A patent/HUE063981T2/hu unknown
- 2018-01-12 ES ES18703122T patent/ES2960030T3/es active Active
- 2018-01-12 US US16/477,623 patent/US11541133B2/en active Active
- 2018-01-12 FI FIEP18703122.4T patent/FI3568205T3/fi active
- 2018-01-12 AU AU2018207190A patent/AU2018207190B2/en active Active
- 2018-01-12 DK DK18703122.4T patent/DK3568205T3/da active
- 2018-01-12 CA CA3050094A patent/CA3050094C/en active Active
- 2018-01-12 KR KR1020197023200A patent/KR102296752B1/ko active IP Right Grant
- 2018-01-12 PL PL18703122.4T patent/PL3568205T3/pl unknown
- 2018-01-12 JP JP2019558997A patent/JP7084417B2/ja active Active
- 2018-01-12 WO PCT/US2018/013640 patent/WO2018132751A1/en active Application Filing
- 2018-01-12 CN CN201880016106.7A patent/CN110678227B/zh active Active
- 2018-01-12 SI SI201831005T patent/SI3568205T1/sl unknown
- 2018-01-12 EP EP18703122.4A patent/EP3568205B1/en active Active
- 2018-01-12 RS RS20231056A patent/RS64815B1/sr unknown
-
2019
- 2019-07-11 IL IL268012A patent/IL268012B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3568205T3 (pl) | 2024-03-18 |
| FI3568205T3 (fi) | 2023-11-01 |
| US20190336623A1 (en) | 2019-11-07 |
| LT3568205T (lt) | 2024-02-12 |
| IL268012B (en) | 2021-12-01 |
| SI3568205T1 (sl) | 2023-12-29 |
| CN110678227A (zh) | 2020-01-10 |
| CA3050094C (en) | 2024-01-02 |
| AU2018207190A1 (en) | 2019-08-29 |
| CN110678227B (zh) | 2023-03-21 |
| CA3050094A1 (en) | 2018-07-19 |
| KR102296752B1 (ko) | 2021-09-02 |
| JP2020505445A (ja) | 2020-02-20 |
| PT3568205T (pt) | 2023-10-26 |
| WO2018132751A1 (en) | 2018-07-19 |
| AU2018207190B2 (en) | 2020-12-03 |
| DK3568205T3 (da) | 2023-10-09 |
| HRP20231458T1 (hr) | 2024-05-10 |
| JP7084417B2 (ja) | 2022-06-14 |
| IL268012A (en) | 2019-09-26 |
| HUE063981T2 (hu) | 2024-02-28 |
| KR20200016196A (ko) | 2020-02-14 |
| EP3568205B1 (en) | 2023-08-16 |
| ES2960030T3 (es) | 2024-02-29 |
| US11541133B2 (en) | 2023-01-03 |
| EP3568205A1 (en) | 2019-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE063981T2 (hu) | Szomatosztatin receptorokat túlexpresszáló rákos sejtek kezelése radioizotópokkal kelátképzett oktreotid-származékok alkalmazásával | |
| IL283733A (en) | Methods for treating cancer using activated t cells | |
| HK1247202A1 (zh) | 用於治療癌症的化合物 | |
| IL282655A (en) | Methods of treating developmental disorders using pipradrol | |
| IL263678B (en) | Compounds for use in the treatment of breast cancer +ar | |
| HK1223557A1 (zh) | 用於治療局部晚期或轉移性雌激素受體陽性乳腺癌的雌激素受體調節劑 | |
| PT3063173T (pt) | Anticorpos anti-cd38 específicos para o tratamento de cancros humanos | |
| SI3473263T1 (sl) | Kombinirani pripravki za zdravljenje raka | |
| EP3386522A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER | |
| IL247436A0 (en) | Preparations and methods for treating tumors that overexpress her2/neu | |
| SG11201701051RA (en) | A method for prognosis of ovarian cancer, patient's stratification | |
| IL282701A (en) | Methods for the synthesis of a radionuclide complex | |
| HK1251009B (zh) | 用於治療癌症的治療組合物 | |
| HK1253082A1 (zh) | 診斷乳腺癌的方法 | |
| IL277235A (en) | Preparations containing octreotide for the treatment of acromegaly | |
| IL266917A (en) | Methods for treating prolactin receptor-positive breast cancer | |
| IL258671A (en) | A therapeutic agent for breast cancer | |
| ZA201802831B (en) | Composition for the treatment of igf-1r expressing cancer | |
| PT3296294T (pt) | Composto para tratamento ou prevenção do cancro de mama | |
| LT2809327T (lt) | Hidroksialkilo krakmolas, skirtas vėžio gydymui, sumažinant naviko augimo greičius | |
| IL246540A0 (en) | Freezeald receptor antibodies for cancer treatment | |
| IL259781A (en) | Uses of pyrimido-pyridazinones to treat cancer | |
| EP3121274A4 (en) | METHOD FOR PREDICTING RESPONSIVENESS TO CANCER TREATMENT USING p300-INHIBITING COMPOUND | |
| EP3387443A4 (en) | INTEGRATED ANALYSIS TO DETERMINE PROGNOSIS AFTER THE TREATMENT OF PRIMARY BREAST CANCER | |
| IL255167A0 (en) | Compounds for the treatment of cancer |